Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | EED | O75530 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SLC18A2 | Q05940 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26309889 | 1.00 | PARP1 (0.40) | PARP1EEDDRD1ERN1GAA | |
| SCHEMBL24842638 | 0.81 | ALDH1A1 (0.48) | ERN1GAA | |
| SCHEMBL26239694 | 0.81 | ALDH1A1 (0.48) | ERN1GAA | |
| SCHEMBL24842946 | 0.81 | ALDH1A1 (0.48) | ERN1GAA | |
| SCHEMBL24698046 | 0.78 | ERN1 (0.39) | PARP1ERN1GAAHTR2A | |
| SCHEMBL21178394 | 0.78 | ERN1 (0.39) | PARP1ERN1GAAHTR2A | |
| SCHEMBL26309890 | 0.73 | PARP1 (0.38) | PARP1DRD1 | |
| SCHEMBL26309891 | 0.73 | PARP1 (0.38) | PARP1DRD1 | |
| SCHEMBL24698045 | 0.72 | HTR1A (0.39) | ERN1HTR2A | |
| SCHEMBL21178823 | 0.72 | HTR1A (0.39) | ERN1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | PARP1 2933/4885EED 4034/4885DRD1 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.